notfred Posted October 4, 2009 Share Posted October 4, 2009 From the Biovail web site: Wellbutrin XL ® Launched in the U.S. by GlaxoSmithKline (GSK), in September 2003, Wellbutrin XL®, an extended-release formulation of bupropion indicated as first-line therapy for the treatment of depression in adults, was well received by U.S. physicians and by the end of 2006, had captured 59% of all bupropion prescriptions in the U.S. Pursuant to Biovail’s manufacturing and supply agreement with GSK, the Company received a tiered supply price that was based on GSK’s net sales of Wellbutrin XL® in any given year. However, as a result of the May 2009 acquisition of full U.S. rights to Wellbutrin XL® , Biovail will now record 100% of U.S. revenues from the product. In January 2007, GSK announced the first European approval for Wellbutrin XR® (the brand name that GSK will use in a number of countries for our once-daily formulation of bupropion hydrochloride) in The Netherlands for the treatment of adult patients with major depressive episodes. Since then, Wellbutrin XR® has been launched in a number of European countries, including Germany, Italy, Spain, Sweden, Netherlands, Norway, Austria, Iceland, Poland, Portugal and Greece. Biovail manufactures and supplies Wellbutrin XR® to GSK at fixed contractual supply prices. According to the Orange Book GSK still makes Wellbutrin and Wellbutrin SR and only Biovail makes Well butrin XL. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.